# Comparative Effects of Aspirin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease

> **NCT07338331** · NA · COMPLETED · sponsor: **Galala University** · enrollment: 80 (actual)

## Conditions studied

- Diabete Type 2
- Non Alcoholic Fatty Liver

## Interventions

- **DRUG:** Aspirin
- **DRUG:** Dapagliflozin (10Mg Tab) along with standard medical therapy

## Key facts

- **NCT ID:** NCT07338331
- **Lead sponsor:** Galala University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-04
- **Primary completion:** 2025-04-05
- **Final completion:** 2025-09-19
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07338331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07338331, "Comparative Effects of Aspirin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07338331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*